We then measured the levels of surface HLA-peptide complexes in two human NSCLC cell lines (e.g. A549 and PC9) with or without targeted TAP1 and/or TAP2 downregulation using a pool containing 4 different small interference RNAs (siRNAs). The gene discussed is TAP1; the disease is non-small cell lung carcinoma.